How Can the Evolution of Trials & Guidelines in Pulmonary Hypertension Inform Future Efforts in IPF/ILD?

  • Lessons from the evolution of endpoints in PH trials: from 6-minute walk test to composite and patient-centric outcomes
  • Applicability of combination and sequential therapy strategies in IPF/ILD clinical development
  • How changes in PH guidelines have influenced trial design – and what that could mean for future IPF/ILD guidance